New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
The Californer/10361833

AUSTIN, Texas - Californer -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is generating renewed attention across the biotechnology sector with another important research development involving its lead investigational gene therapy, REQORSA®. The company announced November 4 that new research has identified TROP2 expression as a potential predictive biomarker for response to REQORSA, adding another important dimension to its developing precision-medicine strategy for lung cancer.

The announcement is particularly encouraging because researchers identified a relationship between TROP2 expression and treatment sensitivity across multiple preclinical models of non-small cell lung cancer (NSCLC). The findings were further supported by an analysis of pretreatment tumor biopsies from patients enrolled in a clinical trial evaluating REQORSA.

For Genprex, this represents an important opportunity to build upon its existing clinical research and investigate how biomarker testing could help identify patients most likely to benefit from treatment. The company is working toward a more personalized approach to cancer therapy, an area receiving increasing attention throughout the oncology industry.

The new research is scheduled to be presented November 18–20 at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

New TROP2 Findings Add Momentum to REQORSA

The November 4 announcement highlights the potential importance of TROP2 expression in determining sensitivity to REQORSA.

Researchers found that low TROP2 expression was consistently associated with primary resistance to REQORSA across multiple preclinical NSCLC models. Analysis of pretreatment tumor biopsies from clinical-trial participants provided additional support for these observations.

The findings are important because biomarkers may help researchers better understand why certain patients respond differently to cancer treatments.

If additional research confirms these relationships, TROP2 testing could become an important component of patient selection for future REQORSA clinical studies.

Genprex is also investigating PTEN, another important biomarker associated with treatment response. Together, these research efforts demonstrate the company's interest in combining innovative gene therapy with more targeted approaches to cancer treatment.

Roche Diagnostics Collaboration: A Significant Strategic Relationship

One of Genprex's most important developments this year is its collaboration with Roche Diagnostics, announced August 3.

More on The Californer

• SD2 Receives $100,000 Grant to Expand STEM Opportunities for San Diego Students
• Brand Identity: Creating a Distinctive Presence in a Competitive Market
• Dental Surgery Solutions: Restoring Oral Health and Function at Coastal Dental Arts in San Diego
• Get Care at Home Partners with PocketRN to Help Dementia Caregivers Find Support at Home
• CareVantage Solutions Adds Five Short Guides and Five Regular Books to The Caregiver Library

The partnership focuses on validating biomarker assays designed to help identify appropriate patients for Genprex's NSCLC clinical program.

Roche brings extensive diagnostic expertise to the collaboration, while Genprex contributes its developing gene therapy platform and growing body of biomarker research.

The initial work centers on two important biomarkers:

• TROP2: Being investigated for its potential ability to identify patients more likely to respond to REQORSA.
• PTEN: A tumor-suppressor protein whose expression has also demonstrated an association with treatment response in previous research.

Roche Diagnostics will conduct assay validation using its TROP2 antibody. Genprex anticipated completion of these studies around the end of 2026, with potential integration into its NSCLC clinical program following successful validation.

This collaboration is especially noteworthy because it connects Genprex with an established global diagnostics organization while advancing a more sophisticated patient-selection strategy.

The ultimate objective is to better identify patients who may benefit from REQORSA and potentially improve the precision of future clinical studies.

REQORSA: Advancing an Innovative Approach to Lung Cancer

At the center of Genprex's oncology strategy is REQORSA, also known as quaratusugene ozeplasmid.

The investigational gene therapy is designed to deliver the TUSC2 tumor-suppressor gene into cancer cells using Genprex's proprietary ONCOPREX Delivery System, which utilizes lipid-based nanoparticles.

TUSC2 is frequently reduced or absent in several forms of lung cancer. REQORSA is designed to restore tumor-suppressor activity and influence multiple biological pathways involved in cancer progression.

Genprex is investigating REQORSA through its Acclaim clinical development program.

Acclaim-1 evaluates REQORSA in combination with AstraZeneca's Tagrisso in patients with advanced NSCLC carrying specific EGFR mutations.

Acclaim-3 evaluates REQORSA in an extensive-stage small cell lung cancer treatment strategy.

Both programs represent important components of the company's longer-term oncology ambitions. The programs have received FDA Fast Track designations, and the small cell lung cancer program has also received Orphan Drug Designation.

These designations provide important regulatory development pathways as Genprex continues its clinical research.

TUSC2 Research Creates Additional Scientific Interest

Genprex is also expanding its scientific investigation of TUSC2 through its sponsored research collaboration with Meharry Medical College.

On November 4, research titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program" is scheduled for presentation at the Gerontological Society of America's 2026 Annual Scientific Meeting.

The research explores TUSC2's relationship with mitochondrial biology, cellular resilience and biological processes associated with aging.

More on The Californer

• Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
• Thursday's Hair Solutions Launches New Program to Address GLP-1-Related Hair Loss
• Two Moorpark College programs named national Bellwether Award finalists
• G. A. Tierney Expands the Dark Psychological Romance Nadine Wolfe Series with Audiobook and Second Novel, The Cruelty of Desire
• Piper Madison Announces New Single "Don't Be a Stranger" and Launch of 10PM Records

This follows an October 21 peer-reviewed publication examining TUSC2's role in maintaining cellular function during brain aging.

These developments add another dimension to the company's scientific platform by examining the broader biological functions of the gene central to REQORSA.

While additional research is necessary to establish any potential therapeutic applications beyond oncology, the work demonstrates continued scientific interest in TUSC2.

Diabetes Gene Therapy Adds Another Development Opportunity

Beyond cancer, Genprex is pursuing an additional opportunity through its diabetes gene therapy program.

The company's approach uses AAV technology to deliver Pdx1 and MafA genes to the pancreas, with the objective of restoring insulin-producing cell function.

Preclinical studies have produced encouraging findings in Type 1 and Type 2 diabetes models, including improvements in glucose control and insulin-related measures.

On August 18, Genprex announced the selection of a U.S.-based contract development and manufacturing organization to begin manufacturing scale-up for its diabetes gene therapy candidate.

This represents an important development as the company works toward preparing the program for future clinical studies.

Having separate development programs targeting cancer and diabetes gives Genprex multiple areas of potential therapeutic opportunity.

Looking Ahead: Important Catalysts for $GNPX Investors

Genprex has several meaningful milestones approaching:

• November 18–20: Presentation of new TROP2 biomarker research in Barcelona.
• Late 2026: Anticipated completion of Roche Diagnostics biomarker assay validation.
• Continued advancement of the Acclaim oncology clinical programs.
• Additional TUSC2 research and scientific collaboration developments.
• Continued manufacturing scale-up for the diabetes gene therapy program.

Genprex Is Building an Intriguing Gene Therapy Story

Genprex brings together several important areas of biotechnology innovation: precision lung cancer treatment, gene therapy, biomarker-guided patient selection and diabetes research.

The latest TROP2 findings add another important piece to the REQORSA development story, while the Roche Diagnostics collaboration provides a valuable strategic relationship as the company works toward more personalized cancer treatment approaches.

With additional scientific presentations ahead, continued clinical development and a second therapeutic program targeting diabetes, Genprex has multiple opportunities to demonstrate further progress.

For investors following emerging biotechnology companies, GNPX presents an evolving story centered on innovative science, strategic collaboration and the pursuit of potentially important new treatment options. The coming months could be especially meaningful as Genprex works to translate its expanding research foundation into further clinical development milestones.

For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/

Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website